首页 / 院系成果 / 成果详情页

Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib Mesylate An Analysis on 22 Chinese Patients 期刊论文

编号：

addb682d-9797-4ab4-bbca-a40338e4d6ed
作者：

Wang, Chunmeng^[1,2] Luo, Zhiguo^[2,3] Chen, Jie^[1,2] Zheng, Biqiang^[1,2] Zhang, Ruming^[1,2] Chen, Yong^[1,2] Shi, Yingqiang^[1,2]
语种：

English
期刊：

MEDICINE ISSN：0025-7974 2015 年 94 卷 17 期 ; MAY
收录：
摘要：

Dermatofibrosarcoma protuberans (DFSP) is a rare, plaquelike tumor of the cutaneous tissue occurring more on the trunk than the extremities and neck. More than 95% of DFSP present anomalies on the 17q22 and 22q13 chromosomal regions leading to the fusion of COL1A1 and PDGFB genes. Surgery is the optimal treatment for DFSP, but less effective in locally advanced or metastatic patients, as is the case with chemotherapy and radiotherapy. The aim of this study was to assess retrospectively thetherapeuticactivityandsafetyofimatinibon22Chinese patients with locally inoperative or metastaticDFSP at a single institution. In the collected data of 367 Chinese patients with DFSP, we analyzed retrospectively 22 patients with locally advanced or metastatic DFSP, all of whom received imatinib therapy at 1 center from January 2009 to October 2014. Patients were administered with imatinib at an initial dose of 400mg and escalated to 800mg daily after they developed imatinib resistance. The median follow-up time was 36 months, and the median treatment time was 15 months. The results showed that 10 locally advanced DFSP patients and 12 metastatic DFSP patients received imatinib therapy. Apart from 1 patient who developed primary imatinib resistance, 15 patients achieved partial remission (PR), and 6 patients achieved stable disease (SD). Both fibrosarcomatous DFSP and classic DFSP patients demonstrated similar response to imatinib. Median PFSwas estimated to be 19months. Median overall survival (OS) has not been reached, and estimated 1-and 3-year OS rates were 95.5%(21/22) and 77.3% (17/22), respectively. Four out of 10 patients with primarily unresectable DFSP received complete surgical resection after neoadjuvant treatment of imatinib. Imatinib therapy is well tolerated with a safety profile and is the therapy of choice in locally inoperative or metastatic DFSP. Neoadjuvant treatment of locally advanced or metastatic DFSP with imatinib improves surgical outcomes and may facilitate resection of difficult tumors.
推荐引用方式
GB/T 7714：

Wang Chunmeng,Luo Zhiguo,Chen Jie, et al. Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib Mesylate An Analysis on 22 Chinese Patients [J].MEDICINE,2015,94(17).
APA：

Wang Chunmeng,Luo Zhiguo,Chen Jie,Zheng Biqiang,&Shi Yingqiang.(2015).Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib Mesylate An Analysis on 22 Chinese Patients .MEDICINE,94(17).
MLA：

Wang Chunmeng, et al. "Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib Mesylate An Analysis on 22 Chinese Patients" .MEDICINE 94,17(2015).

浏览次数：13  下载次数：0

分享到：

浏览次数：13

下载次数：0

打印次数：0